NCT04889716 2026-03-18
CAR-T Followed by Bispecific Antibodies
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
Clinical Trials
11 trialsNCT06846463 2026-01-23
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
Virginia Commonwealth University
Phase 2 Recruiting
NCT07288879 2026-01-08
DALY II Japan
Miltenyi Biomedicine GmbH
Phase 2 Recruiting
NCT06736613 2025-12-18
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07255963 2025-12-01
Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
NCT06891157 2025-03-24
Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06151080 2025-02-19
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT06158399 2025-02-19
AZA Combined With RCHOP in P53-mutated DLBCL.
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT05641428 2024-09-23
HOVON161
University Medical Center Groningen
Phase 2 Recruiting
NCT06534762 2024-08-02
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
Zhejiang Provincial People's Hospital
Phase 2 Recruiting
NCT06287398 2024-07-22
Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL
Australasian Leukaemia and Lymphoma Group
Phase 2 Recruiting